TABLE II -.
Ranking according to the surface under the cumulative ranking curve and mean rank for the tolerability outcomes
| Treatment | Surface under the cumulative ranking curve | Mean rank |
|---|---|---|
| At least one treatment-emergent adverse event | ||
| Brivaracetam | 67.0 | 2.6 |
| Cenobamate | 21.5 | 4.9 |
| Eslicarbazepine acetate | 12.8 | 5.4 |
| Lacosamide | 70.2 | 2.5 |
| Perampanel | 29.6 | 4.5 |
| Placebo | 98.8 | 1.1 |
| At least one treatment-emergent adverse event leading to discontinuation | ||
| Brivaracetam | 62.3 | 2.9 |
| Cenobamate | 11.9 | 5.4 |
| Eslicarbazepine acetate | 24.8 | 4.8 |
| Lacosamide | 56.8 | 3.2 |
| Perampanel | 44.5 | 3.8 |
| Placebo | 99.7 | 1.0 |
Higher values of surface under the cumulative ranking curve correspond to higher probabilities of better tolerability.